NVCT
NuvectisCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
If NXP900's Phase 1b program begins to show biomarker-linked activity in enrolled monotherapy or EGFR-combination cohorts, NVCT could re-rate because management has described active enrollment in key Phase 1b studies and the latest confirmed financial update indicates runway through several of those milestones [#8-K-2026-02-11].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
As of 2026-05-04, no verified Q1 2026 earnings release or 10-Q was available in the evidence packet, leaving surprise, guidance, and market-reaction evidence unavailable.
Momentum
88
Value
41
Sentiment
35
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.50 · Bull $14.00 · Bear $4.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-05-29 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $18.20
Why
Momentum88 · Δ7d -
Value41 · Δ7d +0.1
Sentiment35 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
88
34% active weight
Current posture
7d trendSoftening
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
35
33% active weight
Current posture
7d trendImproving
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 88.2 / Value 41.1 / Sentiment 35.0
Fundamentals (TTM)As of 2026-05-29
Fundamentals (TTM)
As of 2026-05-29
Market Cap
$258.62M
Beta
-0.31
Shares Out
25.61M
P/E (TTM) · Derived
-7.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-14.24
Rev YoY
-
EPS YoY
-80.6%
Gross Margin
-
Op Margin
-
Net Debt
-$18.53M
Current Ratio
3.07
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology